Skip to Content

A New Approach to Boosting Good Cholesterol

Activating longevity-linked genes could protect against atherosclerosis.
October 12, 2007

Hoping to repeat the blockbuster success of cholesterol-lowering statins, pharmaceutical companies have been doggedly searching for a new kind of cholesterol drug–one that pumps up levels of heart-healthy good cholesterol. High levels of bad cholesterol (LDL) build up in the arteries and lead to heart attacks, while good cholesterol (HDL) appears to protect against cardiovascular disease, likely by flushing away its harmful cousin.

But finding such drugs has been a challenge. One promising, high-profile candidate from Pfizer, called torcetrapib, was pulled from development last year when clinical trials revealed serious safety concerns. And derivatives of niacin, a B vitamin shown to boost good cholesterol, has problematic side effects that stop many people from taking the drug.

New research from Leonard Guarente at MIT could provide a new target for HDL-raising drugs: the sirtuins, a class of genes linked to longevity. (See “The Enthusiast” and “The Fountain of Health.”) According to Guarente, SIRT1 can promote formation of good cholesterol and lowers the cholesterol burden in tissues by removing excess cholesterol from those tissues and flushing it out of the body. The findings were published today in the journal Molecular Cell.

Sirtris Pharmaceuticals, a company based in Cambridge, MA, that’s developing novel compounds that target the sirtuins, has already licensed the patent covering the research from MIT. Sirtris already has one sirtuin-activating compound in early clinical trials for diabetes.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.